WaveBreak Therapeutics

WaveBreak Therapeutics (formerly known as Wren Therapeutics) is a biopharmaceutical company pioneering a chemical kinetics-based approach to drug discovery for protein misfolding diseases. Spun out from the University of Cambridge, the company utilizes a proprietary platform to identify small molecules that specifically inhibit the microscopic processes leading to toxic protein aggregation. Their primary focus is on neurodegenerative conditions such as Alzheimer's and Parkinson's diseases, where they target proteins like amyloid-beta and alpha-synuclein. By quantifying the rates of individual reaction steps in protein aggregation, WaveBreak aims to develop highly potent and selective therapies that can intervene at the earliest stages of disease progression.